Why is OneSource Specialty Pharma Ltd ?
- The company has been able to generate a Return on Equity (avg) of 0.80% signifying low profitability per unit of shareholders funds
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.29
- The company has been able to generate a Return on Equity (avg) of 0.80% signifying low profitability per unit of shareholders funds
- PBT LESS OI(Q) At Rs 20.79 cr has Grown at 185.7% (vs previous 4Q average)
- PAT(Q) At Rs 29.30 cr has Grown at 283.5% (vs previous 4Q average)
- NET SALES(Q) At Rs 449.02 cr has Grown at 26.3% (vs previous 4Q average)
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -9.22%, its profits have fallen by -80%
How much should you hold?
- Overall Portfolio exposure to OneSource Speci. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is OneSource Speci. for you?
High Risk, Medium Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
At Rs 20.79 cr has Grown at 185.7% (vs previous 4Q average
At Rs 29.30 cr has Grown at 283.5% (vs previous 4Q average
At Rs 449.02 cr has Grown at 26.3% (vs previous 4Q average
Highest at Rs 123.35 cr.
Highest at Rs 2.18
At Rs 33.87 cr has Grown at -66.75%
At Rs 30.81 cr has Grown at 36.87%
Here's what is working for OneSource Speci.
PBT less Other Income (Rs Cr)
PAT (Rs Cr)
Net Sales (Rs Cr)
Net Sales (Rs Cr)
Operating Profit (Rs Cr)
PBT less Other Income (Rs Cr)
PAT (Rs Cr)
EPS (Rs)
Here's what is not working for OneSource Speci.
Interest Paid (Rs cr)






